You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海医药(601607.SH):Prolgolimab 注射液获批III期临床试验
格隆汇 02-22 16:42

格隆汇2月22日丨上海医药(601607.SH)公布,近日,公司合资公司上药博康生物医药(香港)有限公司(SPH-BIOCAD (HK) Limited,以下简称“上药博康”)开发的“Prolgolimab注射液”收到国家药监局核准签发的《药物临床试验批准通知书》。

“Prolgolimab注射液”是一种以单克隆IgG1抗体为骨架的全人抗PD-1单抗注射液,来源于转基因CHO-S/aPD-1细胞系,是国际上第一款具有Fc沉默“LALA”突变的IgG1抗PD-1单抗,一定程度上降低了可能的副作用。Prolgolimab通过阻断PD-1与配体PD-L1和PD-L2的相互作用,可以增强T细胞抗肿瘤应答,进而使肿瘤缩小。

经上药博康与国家药监局药品审评中心沟通,基于该项目已在俄罗斯上市,国家药监局同意按照已提交的方案开展III期临床试验。上药博康将于近期启动国际多中心晚期非鳞状非小细胞肺癌以及进展性、复发性或转移性宫颈癌成人患者III期临床试验。截至目前,该项目上药博康已累计投入研发费用约151.9万元人民币。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account